• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Beta-blocker therapy in elderly patients with renal dysfunction and heart failure

    2021-03-03 07:32:36JuanMartnezMillaMarcelinoCortGarcJuliaAnnaPalfyMikelTaiboUrquMartapezCastilloAnaDevesaArbiolAnaLucRiveroMonteagudoMarLuisaMartMariscalInJimnezVarasSemBriongosFigueroJuanAntonioFrancoPelaJosTu
    Journal of Geriatric Cardiology 2021年1期
    關(guān)鍵詞:截?cái)嘀?/a>符合率比值

    Juan Martínez-Milla?, Marcelino Cortés García, Julia Anna Palfy, Mikel Taibo Urquía,Marta López Castillo, Ana Devesa Arbiol Ana Lucía Rivero Monteagudo,María Luisa Martín Mariscal, Inés Jiménez-Varas, Sem Briongos Figuero,Juan Antonio Franco-Pelaéz, José Tu?ón,7,8

    1. Department of Cardiology, Hospital Universitario Fundación Jiménez Díaz-Quirónsalud; 2. Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain; 3. Department of Cardiology, Hospital Central de Asturias; 4. Department of Cardiology, Hospital Universitario Ruber-Quirónsalud; 5. Department of Cardiology, Hospital Universitario Infanta Leonor; 6. Department of Endocrinology, Hospital Clínico San Carlos; 7. Universidad Autónoma de Madrid; 8. CIBERCV,Madrid, Spain

    ABSTRACT OBJECTIVE To assess the role of beta-blockers (BB) in patients with chronic kidney disease (CKD) aged ≥ 75 years.METHODS AND RESULTS From January 2008 to July 2014, we included 390 consecutive patients ≥ 75 years of age with ejection fraction ≤ 35% and glomerular filtration rate (GFR) ≤ 60 mL/min per 1.73 m2. We analyzed the relationship between treatment with BB and mortality or cardiovascular events. The mean age of our population was 82.6 ± 4.1 years. Mean ejection fraction was 27.9% ± 6.5%. GFR was 60?45 mL/min per 1.73 m2 in 50.3% of patients, 45?30 mL/min per 1.73 m2 in 37.4%, and < 30 mL/min per 1.73 m2 in 12.3%. At the conclusion of follow-up, 67.4% of patients were receiving BB. The median follow-up was 28.04 (IR: 19.41?36.67) months. During the study period, 211 patients (54.1%) died and 257 (65.9%) had a major cardiovascular event (death or hospitalization for heart failure). BB use was significantly associated with a reduced risk of death (HR = 0.51, 95%CI: 0.35?0.74; P < 0.001). Patients receiving BB consistently showed a reduced risk of death across the different stages of CKD:stage IIIa (GFR = 30?45 mL/min per 1.73 m2; HR = 0.47, 95% CI: 0.26?0.86, P < 0.000 1), stage IIIb (GFR 30?45 mL/min per 1.73 m2; HR = 0.55, 95% CI: 0.26?1.06, P = 0.007), and stages IV and V (GFR < 30 mL/min per 1.73 m2; HR = 0.29, 95% CI: 0.11?0.76; P =0.047).CONCLUSIONS The use of BB in elderly patients with HFrEF and renal impairment was associated with a better prognosis.Use of BB should be encouraged when possible.

    Heart failure (HF) is one of the most prevalent cardiovascular (CV) disorders worldwide. Approximately half of all patients with HF have reduced or mid-range ejection fraction.[1,2]Due to their negative inotropic action, for many years beta-blockers (BB) were contraindicated in patients with HF. Toward the end of the last century, however, these drugs were shown to have highly positive effects in patients with HF.Since then, they have become a cornerstone in the treatment of HF with systolic dysfunction,[3]and the most recent clinical practice guidelines encourage BB use to reduce mortality and CV events.[4,5]

    Despite such advances, data remain scarce on the role of these drugs in elderly patients with chronic kidney disease (CKD). Classically, both elderly and CKD patients have been underrepresented in clinical trials, creating a gap in the evidence base. In addition, CKD is highly prevalent among elderly patients with HF and reduced ejection fraction(HFrEF).[6]As a result, though HF drugs (e.g., Angiotensin-Converting Enzyme inhibitors (ACEi)/Angiotensin Receptor Blockers (ARB), BB, Mineralocorticoid Receptor Antagonist (MRA), Angiotensin Receptor-Neprilysin Inhibitors (ARNI))provide a substantial cardiovascular (CV) benefit,the underrepresentation of elderly patients with CKD in the primary clinical trials and the existence of side effects may limit their use.[6,7]As well as ACEi/ARB and MRA,[8]the elderly may be less likely to receive BB than other populations with HFrEF,particularly in cases with associated CKD, despite the fact that there is no clear reason to avoid this medication.[9]Our study analyzes the role of BB therapy in elderly patients with HFrEF and CKD.

    METHODS

    Patients

    We carried out a single-center, observational cohort study. From January 2008 to July 2014, we consecutively enrolled 802 patients 75 years of age or older with left ventricular ejection fraction (LVEF) ≤35% as measured by 2-dimensional echocardiography. Of the total population, 390 had renal impairment, defined as a glomerular filtration rate(GFR) < 60 mL/min per 1.73 m2.

    A specific database compiled in the cardiac imaging department of Hospital Fundación Jiménez Díaz (Madrid, Spain) was used to screen for patients meeting both criteria. All patients underwent regular medical supervision according to their symptoms and the indications of their physician(cardiologists or general practitioners) to optimize treatment.

    This investigation was carried out in accordance with the principles outlined in the Declaration of Helsinki.

    Outcomes and Follow-up

    The outcomes analyzed in our study were the rate of all-cause death and major CV events. Here,CV events included death from any cause or admission due to HF. HF admission was defined as admission to a health-care facility lasting > 24 h due to the worsening of HF symptoms and followed by specific treatment for HF (regardless of the cause of cardiac decompensation). Data on clinical events and death during follow-up were collected from patients’ electronic health records or, if unavailable,from telephone interviews with patients or relatives.

    Statistical Analysis

    Data were subjected to descriptive statistical analysis via frequency measurements (absolute frequencies and percentages) for qualitative variables and using mean and standard deviation for quantitative variables. The magnitude of the effects of the variables was expressed as hazard ratio (HR) and 95% confidence interval (95% CI). Univariate analysis of the quantitative variables was performed using the Student t test when the variables were normally distributed, and the Mann-Whitney U test when distribution was not normal. Qualitative variables were analyzed using the χ2or the Fisher exact test.

    Because observational studies do not allow for randomization, we planned 2 different approaches to avoid potential confounding factors: multivariate Cox proportional hazard and propensity score(PS)-matched analysis. These two analyses were used to determine significant predictors of CV events and mortality. First, we performed a multivariate analysis with Cox (backward stepwise) regression. Of all the baseline variables collected, we selected those with the potential to act as confounding factors. The selection criteria were as follows:first, clinical and biological plausibility and, second,the statistical criterion of Mickey, excluding all those variables that returned a P value > 0.20 on univariate analysis. Second, we performed a PS-matched analysis. The PS was calculated by means of an ordered logistic regression model, taking the BB group as the dependent variables and adopting a parsimonious approach. In a first step, all the following variables were included in the univariate analysis: age, gender, hypertension, diabetes mellitus, obesity, GFR, chronic obstructive pulmonary disease (COPD), peripheral vascular disease, any degree of cognitive impairment, any degree of functional disability, ischemic origin of reduced EF, previous HF admission, sinus rhythm, wide QRS complex, LVEF, and New York Heart Association (NYHA)Class I or II (vs. III, IV, or not available) at initiation of follow-up. All variables with a P-value < 0.2 were entered into a multivariate binary logistic regression model, which served to estimate the PS of every patient. Patient matching was performed at a 1:1 ratio with the nearest neighbor method (caliper =0.2 × SD [logitPs]).

    Results are expressed as hazard ratio (HR) and 95% CI. Statistical analyses were performed with SPSS version 22.0 (SPSS, Inc, Chicago IL, USA).

    RESULTS

    Baseline Characteristics

    During the study period, 802 consecutive patients with LVEF ≤ 35% were assessed for eligibility.Of these, 390 patients were included due to associated renal impairment. Table 1 shows the baseline characteristics of our population. In terms of sex,62.3% were male, and the mean age was 82.6 ± 4.1 years. Mean LVEF was 27.9% ± 6.5%. An ischemic etiology was found in 50.6% of cases. GFR was between 60 and 45 mL/min per 1.73 m2in 50.3% of patients, 45?30 mL/min per 1.73 m2in 37.4%, and <30 mL/min per 1.73 m2in 12.3%.

    At the end of follow-up (32 ± 23 months), 263(67.4%) patients were undergoing treatment with BB. The most commonly used BB by type was bisoprolol once daily in 143 (54.4%) patients followed by carvedilol twice daily in 111 (42.2%) patients,metoprolol twice daily in 6 (2.3%) patients, and nebivolol once daily in 3 (1.1%) patients. Chronic lung disease (32.4%), followed by bradycardia (9.0%), asthenia (4.5%), and deterioration of HF (4.5%) were the most frequent reasons why study subjects did not take BB; however, in 29.7% of these patients no formal contraindication was found. Dose levels of BB used are shown in Table 2 for both the entire population and according to GFR.

    2.3 驗(yàn)證預(yù)測(cè)效果 驗(yàn)證組平均sFlt-1(3 207.79±3 206.82)pg/ml,平均PLGF(729.30±756.96)pg/ml,平均sFlt-1/PLGF(12.87±22.76),取sFlt-1/PLGF比值12.68作為截?cái)嘀?,統(tǒng)計(jì)出驗(yàn)證組的靈敏度為80.0%,特異度為92.6%,符合率為90.6%。

    Outcomes

    After a median follow-up of 28.04 (IR: 19.41?36.67) months, 211 patients (54.1%) died and 257 patients (65.9%) developed a major CV event (death or hospitalization for HF). Of the patients who died,the cause of death was CV in 56 cases (26.5%), and non-CV causes accounted for 73 deaths (34.6%). We were unable to determine the cause of death in 82 patients (38.9%). Regarding HF hospitalization alone, 146 patients (37.4%) of the total study population were admitted due to HF decompensation.We performed a multivariate analysis (Cox regression) of our study population in order to identify significant predictors of total mortality, following the methodology described above. In similar fashion, we performed another multivariate analysis(Cox regression) to determine significant predictors of CV events. Tables 3 and 4 show the results of univariate and multivariate analyses of overall mortality (Table 3) and CV events (Table 4). A multivariate Cox regression analysis revealed that the use of BB was significantly associated with lower mortality rates (HR = 0.53, 95% CI: 0.37?0.78, P logrank < 0.001), as compared with patients not receiving BB (Figure 1A). However, BB use was not significantly associated with differences in CV events.When we used propensity score matching specifically aimed at analyzing the role of BB in our population, we found that BB had benefited our population, producing a difference that reached statistical significance (HR = 0.45, 95% CI: 0.27?0.75, P =0.002) (Figure 1B). Similarly, we found no relationship between BB and CV events. Finally, a multivariate Cox analysis considering HF hospitalization alone revealed no relation between BB and a reduction in HF admissions; only ACEi/ARBs played a protective role in this regard (HR = 0.467; 95%CI: 0.313?0.696).

    When we analyze the role of BB according to eGFR, we see similar results throughout the study population. In the subgroup of patients with stage IIIa CKD (GFR 45?60/min per 1.73 m2), BB significantly reduced mortality (HR = 0.47; 95% CI:0.26?0.86; P log-rank < 0.000 1); the same was true for patients with stage IIIb (GFR = 30?45/min per 1.73 m2; HR = 0.55, 95% CI: 0.26?1.06; P log-rank =0.007) and stages IV and V disease (GFR < 30 mL/min per 1.73 m2; HR = 0.29, 95% CI: 0.11?0.76; P log-rank =0.047) (Figure 2).

    When we analyzed the population by BB dose, no differences in the mean dose of bisoprolol and carvedilol were found between the different glomerular filtration groups. A similar analysis was not done for metoprolol and nebivolol because of their low rate of use in our population.

    Table 1 Baseline characteristics.

    DISCUSSION

    Blocking the adrenergic system with BB has proven effectiveness in patients with HFrEF,[3]and this treatment is currently included in clinical guidelines.[4,5]A closer look at the studies reporting evidence in support of using these drugs, however,reveals that the populations studied present a relatively low number of comorbidities, with few patients over 75 years of age (average age commonly under 65 years),[10,11]making these studies unrepresentative of routine clinical practice.[12]Elderly patients make up a substantial portion of the population with severe left ventricular dysfunction,[9]and the rate of renal failure in this cohort is often 3-fold higher than that of the general population.[13]In addition, these patients have a higher proportion of other comorbidities and polypharmacy, and more than 70% of HF patients older than 80 years fulfil frailty criteria.[14,15]These differences are important to bear in mind when interpreting the results of randomized clinical trials on BB, and nowadays, specific data remain limited and controversial.[16]

    Table 2 Daily doses of beta-blockers used.

    Table 3 Univariate and multivariate analysis of overall mortality.

    Although the available evidence on BB therapy in patients > 70 years with HFrEF is limited, recent studies support the use of these drugs. The SENIORS trial compared the use of BB against a placebo in patients over 70 years of age with HF;[17]all patients included in the study had a clinical history of chronic HF with one or both of the following features: documented hospital admission within the previous 12 months with a discharge diagnosis of congestive HF or documented LVEF ≤ 35% within the previous 6 months. The trial demonstrated a correlation between nebivolol use and a significant(14%) reduction of the primary end-point, a composite of all-cause mortality or cardiovascular hospital admission. Though a secondary end-point, no favorable impact of nebivolol on all-cause mortality was demonstrated (HR = 0.88, 95% CI: 0.71?1.08;P=0.21).[18]We believe that the main difference between the SENIORS study and both our study and pivotal clinical trials is the inclusion of patients with preserved LVEF, since 35% of patients were reported to have LVEF > 35%. In fact, no treatment has demonstrated a clear survival benefit among patients with preserved LVEF-HF.[4,5]There is a lack of robust data evidencing decreased mortality associated with BB administration in the elderly population. Hernandezet al., in the OPTIMIZE-HF registry, suggest that BB are beneficial in elderly patients with HFrEF.[16]Few studies have reported clear benefit of BB in elderly population in terms of mortality. Our group conducted a retrospective, observational study in elderly patients (> 75 years) with HFrEF, concluding that BB therapy improves survival in patients with LVEF lesser than or equal to 0.35, although this effect seems unrelated to the dose received (P= 0.025).[18]

    Table 4 Univariate and multivariate analysis of cardiovascular events.

    Figure 1 All-cause mortality in overall population. (A): Kaplan-Meier curve showing all-cause mortality in the overall population,comparing the group under beta-blocker therapy (green) against the group not receiving this treatment (blue); (B): Kaplan-Meier curve showing all-cause mortality, comparing the group under beta-blocker therapy (green) versus the group that did not use beta-blockers(blue), after propensity score matching.

    Another issue to take into account when evaluating these patients is CKD status. We know this disorder is more prevalent in patients with HF and has an important influence on prognosis.[19,20]In addition, we know that the presence of CKD in HF patients affects the prescription, dosage, and maintenance of therapies that have demonstrated benefits in HFrEF.[4,5]In addition, advanced-stage CKD was an exclusion criterion in many of the clinical trials analyzing the role of BB therapy in patients with HFrEF.[21]Furthermore, those studies that have examined the role of BB therapy in this group of patients are mostly observational in design, and the endpoints used are less relevant (i.e., other than major factors or nonfatal clinical events).[22,23]Despite this lack in the knowledge base, presence of CKD is one of the primary factors associated with increased mortality.[22]

    Most clinical trials carried out to date use exclusion criteria based on glomerular filtration rate(GFR), and as a result patients with Stage I and II kidney disease are well-represented (GFR > 90 mL/min per 1.73 m2and 60?89 mL/min per 1.73 m2, respectively).[24,25]However, this representativeness decreases at lower GFR, and the available data on patients at stage IV and V are scant.

    This pattern can be seen in the classical studies investigating the role of BB therapy in HFrEF patients with associated Stage-IIIa, Stage-IIIb, and Stage-IV-V CKD(25). Although there is no strong evidence of the effect of BB in CKD, stage III is better represented in the different clinical trials. In the MERIT-HF trial (metoprolol vs placebo), which included patients with HFrEF, there was a significant relative risk reduction in the composite endpoint of CV hospitalization/all-cause mortality in patients with GFR of 45?60 mL/min per 1.73 m2(HR = 0.68(0.52?0.90)) and even in patients with GFR < 45 mL/min per 1.73 m2.[26]

    In the CIBIS-II trial on the effect of bisoprolol in patients with HFrEF, BB significantly reduced the mortality and HF-related hospital stay in the subgroup of patients with GFR <60 mL/min per 1.73 m2as well as those with GFR < 45 mL/min per 1.73 m2.[27]As in the SENIORS trial in patients with reduced GFR, the effect of BB was not different from the effect in patients with GFR above 60 mL/min per 1.73 m2.[28]Finally, a meta-analysis of the effect of carvedilol in the COPERNICUS (Carvedilol Prospective Randomized Cumulative Survival) and CAPRICORN (Carvedilol Post Infarct Survival Control in LV Dysfunction) trials showed that this BB significantly improved outcome in patients with eGFR between 45 and 60 mL/min per 1.73 m2.There was no interaction between the effect of carvedilol treatment and eGFR categories (< 45vs.45 to 60 mL/min per 1.73 m2).[29]

    Stages IV and V are not well-represented, though data from both the MERIT-HF and CIBIS-II trials suggest that BB are effective in patients with CKD stage IIIb-V(26,27). Specially, in the MERIT-HF study, the metoprolol/placebo hazard ratio was 0.41 (95% CI: 0.25 to 0.68) in the 493 patients with eGFR < 45 mL/min per 1.73 m2(12% of the whole study population). This subgroup had a mean eGFR of 36.6 ± 6.8 mL/min per 1.73 m2, which included patients with eGFR < 30 mL/min per 1.73 m2.[26]In the SENIORS study, only 3.1% of patients had stage IV CKD, but no subgroup analysis has been performed on these patients.[28]However, only 8% of all patients in these studies had stage 4 CKD. In a small trial of hemodyalisis patients with HF, carvedilol significantly improved the secondary combined endpoint of all-cause mortality and CV death.[30]

    Recently, Kotecha,et al.[31]published the largest meta-analysis including patients with left ventricular dysfunction and CKD. The authors considered 10 double blind placebo-controlled trials that included more than 16,000 patients. They found that BB reduced the relative risk of all-cause mortality by 27% (95% CI: 0.62?0.86) in patients with GFR of 45?60 mL/min per 1.73 m2and 29% (95% CI:0.58?0.87) in those with a GFR of 30?44 mL/min per 1.73 m2. This benefit was only seen in patients in sinus rhythm. In patients with GFR < 30 mL/min per 1.73 m2there were no enough patients to draw conclusions due to the exclusion criteria of the different trials.[31]

    Concern for increased toxicity often leads clinicians to undertreat these patients with CKD, causing less therapeutic resources to be devoted to individuals with myocardial infarction and concomitant CKD.[32]However, it has been shown that these therapeutic measures are beneficial in this population.[33]

    Our population is particularly elderly (mean age,82.6 ± 4.1 years), and as such is representative of the individuals we treat in our daily practice. There is currently no solid evidence on the role of BB in the elderly population with HF and CKD. Given this lack of data about the role of BB in this common population: elderly with HF and CKD. For this reason, we believe that our findings are relevant for overall practice. We found a significant reduction in all-cause mortality, and this benefit was maintained when separately assessing the role of BB treatment in advanced CKD patients (< 45 mL/min per 1.73 m2), as the protective effect of this treatment continues to be statistically significant in terms of all-cause mortality. The effect of treatment with BB is neutral, however, when we isolate the variable of mortality. The high rate of associated cardiovascular co-morbidities may have attenuated the beneficial effect of BB therapy in our study population in terms of CV events.

    In sum, according to our data, treatment with BB in elderly patients presenting HFrEF and CKD was associated with a lower rate of all-cause mortality.Our data thus show that BB therapy could improve the prognosis of this selected population when there is no formal contraindication for its use.

    STUDY LIMITATIONS

    Our study has certain limitations. First, the study population is relatively small, which could influence the statistical results. In addition, it is a retrospective, non-randomized study using a historical cohort from a single center. A third limitation is the relatively short follow-up period, potentially masking a long-term benefit of BB in reduction of CV events. Nevertheless, this last issue is less relevant due to the short life expectancy of elderly patients and the higher number of CV events they present.Lastly, we were unable to discern the cause of death in 82 (38.7%) patients as this information was lacking from their clinical records.

    CONCLUSIONS

    According to our results, use of BB is significantly associated with a reduction in all-cause mortality in elderly patients with HFrEF and CKD irrespective of GFR. As a result, these drugs may be beneficial for these patients provided there are no formal contraindications. Nevertheless, this is an observational study and that residual confounding may exist.

    ACKNOWLEDGMENTS

    To Oliver Shaw for editing the manuscript for aspects related to English language usage and style.

    猜你喜歡
    截?cái)嘀?/a>符合率比值
    ROC曲線在河源市新生兒G6PD缺乏癥篩查截?cái)嘀抵械膽?yīng)用
    中國(guó)實(shí)用醫(yī)藥(2020年24期)2020-09-24 03:10:13
    彩色多普勒超聲檢查在診斷乳腺良惡性腫瘤中的應(yīng)用價(jià)值
    海南省新生兒先天性甲狀腺功能減低癥流行病學(xué)特征及促甲狀腺激素篩查截?cái)嘀档脑O(shè)定
    CT與MRI在宮頸癌分期診斷中的應(yīng)用效果分析
    CT、MRI在眼眶海綿狀血管瘤與眼眶神經(jīng)鞘瘤影像學(xué)鑒別診斷中的研究
    比值遙感蝕變信息提取及閾值確定(插圖)
    河北遙感(2017年2期)2017-08-07 14:49:00
    不同應(yīng)變率比值計(jì)算方法在甲狀腺惡性腫瘤診斷中的應(yīng)用
    論連分?jǐn)?shù)的應(yīng)用
    雙電機(jī)比值聯(lián)動(dòng)控制系統(tǒng)
    国产亚洲欧美98| 久久久久久九九精品二区国产| 国产免费av片在线观看野外av| 性色av乱码一区二区三区2| 最近在线观看免费完整版| 国产av一区在线观看免费| 91九色精品人成在线观看| 欧美日韩综合久久久久久 | 麻豆av在线久日| 亚洲电影在线观看av| 欧美日本亚洲视频在线播放| 最近视频中文字幕2019在线8| 国产真实乱freesex| 九色国产91popny在线| 一个人看的www免费观看视频| 一级a爱片免费观看的视频| 琪琪午夜伦伦电影理论片6080| 欧美乱妇无乱码| 国产av一区在线观看免费| 成年版毛片免费区| 一a级毛片在线观看| 亚洲性夜色夜夜综合| 熟女人妻精品中文字幕| 99国产精品99久久久久| 国产男靠女视频免费网站| 国产成年人精品一区二区| 丝袜人妻中文字幕| 级片在线观看| 亚洲一区二区三区色噜噜| 免费电影在线观看免费观看| 欧美乱妇无乱码| 日本一本二区三区精品| 亚洲 欧美 日韩 在线 免费| 国产黄a三级三级三级人| 午夜亚洲福利在线播放| 亚洲精品久久国产高清桃花| 日本黄色片子视频| 午夜久久久久精精品| 日日摸夜夜添夜夜添小说| 国产精品1区2区在线观看.| 国产精品香港三级国产av潘金莲| 亚洲黑人精品在线| 精品久久久久久久久久久久久| 老司机在亚洲福利影院| 丰满人妻一区二区三区视频av | 亚洲欧美日韩高清专用| 久久热在线av| 国产一级毛片七仙女欲春2| 97超视频在线观看视频| 精品熟女少妇八av免费久了| 久久久久久久久中文| 亚洲精品在线美女| 精品电影一区二区在线| 首页视频小说图片口味搜索| 99国产精品一区二区蜜桃av| 久久久久国内视频| 亚洲成av人片免费观看| 亚洲欧美激情综合另类| 中文字幕最新亚洲高清| 国产又黄又爽又无遮挡在线| 国产精品一区二区免费欧美| 啦啦啦观看免费观看视频高清| 1024香蕉在线观看| 色综合站精品国产| 狠狠狠狠99中文字幕| 国模一区二区三区四区视频 | 久久精品亚洲精品国产色婷小说| 女同久久另类99精品国产91| 男人舔奶头视频| 亚洲av免费在线观看| 叶爱在线成人免费视频播放| 成人鲁丝片一二三区免费| 一本综合久久免费| 热99在线观看视频| 亚洲色图 男人天堂 中文字幕| 亚洲在线自拍视频| 婷婷精品国产亚洲av在线| 国产三级黄色录像| 搞女人的毛片| 九九久久精品国产亚洲av麻豆 | 欧美日本视频| av天堂中文字幕网| 国产乱人视频| 波多野结衣高清无吗| 五月伊人婷婷丁香| 国产精品,欧美在线| 久久中文字幕一级| 国产精华一区二区三区| 美女高潮的动态| 亚洲人成网站高清观看| 久久精品亚洲精品国产色婷小说| 亚洲中文字幕日韩| 精品久久久久久,| 男女床上黄色一级片免费看| 性色av乱码一区二区三区2| 午夜福利视频1000在线观看| 亚洲成a人片在线一区二区| 大型黄色视频在线免费观看| 国产一区二区激情短视频| bbb黄色大片| 午夜日韩欧美国产| 久久亚洲精品不卡| 国产精华一区二区三区| 9191精品国产免费久久| 在线观看一区二区三区| 禁无遮挡网站| 中文资源天堂在线| 香蕉av资源在线| 欧美成狂野欧美在线观看| 脱女人内裤的视频| 日韩欧美精品v在线| 亚洲欧美日韩卡通动漫| 亚洲人成网站高清观看| 99国产极品粉嫩在线观看| 日韩欧美免费精品| 国产激情久久老熟女| 一级黄色大片毛片| 日本精品一区二区三区蜜桃| 97超级碰碰碰精品色视频在线观看| 一个人看视频在线观看www免费 | 丝袜人妻中文字幕| 国产成人精品久久二区二区免费| 在线观看一区二区三区| 性色avwww在线观看| 淫妇啪啪啪对白视频| 亚洲 国产 在线| 叶爱在线成人免费视频播放| 99热这里只有精品一区 | 两个人视频免费观看高清| 国产成人啪精品午夜网站| 99视频精品全部免费 在线 | 国产乱人伦免费视频| 久久中文看片网| 麻豆成人午夜福利视频| 不卡av一区二区三区| 国产伦精品一区二区三区视频9 | av片东京热男人的天堂| 久久国产精品影院| a级毛片a级免费在线| 少妇的丰满在线观看| 亚洲色图av天堂| 99热只有精品国产| 欧美丝袜亚洲另类 | 香蕉国产在线看| 中文字幕av在线有码专区| 一级a爱片免费观看的视频| 国模一区二区三区四区视频 | 男女之事视频高清在线观看| 国内精品久久久久精免费| 每晚都被弄得嗷嗷叫到高潮| 日日干狠狠操夜夜爽| 国产 一区 欧美 日韩| 麻豆久久精品国产亚洲av| 精品久久久久久久毛片微露脸| 婷婷丁香在线五月| 1000部很黄的大片| 岛国在线免费视频观看| 亚洲 欧美一区二区三区| 亚洲乱码一区二区免费版| 欧美在线一区亚洲| 亚洲av成人精品一区久久| 日韩欧美国产一区二区入口| 国产成人精品无人区| 久久国产精品人妻蜜桃| 最好的美女福利视频网| 国产精品久久视频播放| 亚洲成av人片在线播放无| 99re在线观看精品视频| 成人av在线播放网站| 搞女人的毛片| 天堂√8在线中文| 日本黄色片子视频| av天堂中文字幕网| 叶爱在线成人免费视频播放| 夜夜躁狠狠躁天天躁| 婷婷精品国产亚洲av在线| 国产成人欧美在线观看| 九九在线视频观看精品| 搡老妇女老女人老熟妇| 黑人欧美特级aaaaaa片| 一级a爱片免费观看的视频| 桃红色精品国产亚洲av| 好看av亚洲va欧美ⅴa在| 黄色女人牲交| 热99re8久久精品国产| www日本在线高清视频| 国产精品,欧美在线| av女优亚洲男人天堂 | 性色avwww在线观看| 小蜜桃在线观看免费完整版高清| 国产蜜桃级精品一区二区三区| 欧美日韩一级在线毛片| 麻豆成人av在线观看| 视频区欧美日本亚洲| bbb黄色大片| 婷婷亚洲欧美| 亚洲精品国产精品久久久不卡| 国产单亲对白刺激| 亚洲国产高清在线一区二区三| 听说在线观看完整版免费高清| 法律面前人人平等表现在哪些方面| 国产视频一区二区在线看| 国产精品爽爽va在线观看网站| 午夜成年电影在线免费观看| 亚洲成人精品中文字幕电影| av女优亚洲男人天堂 | 一本一本综合久久| 老熟妇乱子伦视频在线观看| 听说在线观看完整版免费高清| 99久久成人亚洲精品观看| 999久久久国产精品视频| 成人午夜高清在线视频| 亚洲 欧美一区二区三区| 日韩 欧美 亚洲 中文字幕| 制服人妻中文乱码| 久久欧美精品欧美久久欧美| 久久精品91无色码中文字幕| 国产精品亚洲美女久久久| 国产精品,欧美在线| 午夜激情欧美在线| 国产极品精品免费视频能看的| 国产精品女同一区二区软件 | 亚洲av电影在线进入| 色尼玛亚洲综合影院| www.自偷自拍.com| 免费观看的影片在线观看| 成人永久免费在线观看视频| 国产精品九九99| 熟女少妇亚洲综合色aaa.| 日韩欧美 国产精品| 极品教师在线免费播放| 99久久精品一区二区三区| 国产精品av视频在线免费观看| 可以在线观看的亚洲视频| 精品福利观看| 一个人免费在线观看电影 | 国产黄色小视频在线观看| 91老司机精品| 日韩欧美一区二区三区在线观看| 欧美色欧美亚洲另类二区| 一个人看的www免费观看视频| 淫秽高清视频在线观看| 亚洲欧洲精品一区二区精品久久久| 最好的美女福利视频网| 亚洲成人久久爱视频| 变态另类成人亚洲欧美熟女| 欧美zozozo另类| 看片在线看免费视频| 久久这里只有精品中国| 99在线视频只有这里精品首页| 激情在线观看视频在线高清| 女生性感内裤真人,穿戴方法视频| 蜜桃久久精品国产亚洲av| 好男人电影高清在线观看| 亚洲精品久久国产高清桃花| 亚洲色图av天堂| 久久久精品欧美日韩精品| 观看免费一级毛片| 久久久成人免费电影| 在线看三级毛片| 亚洲 欧美 日韩 在线 免费| 亚洲aⅴ乱码一区二区在线播放| 国产1区2区3区精品| 国产伦精品一区二区三区视频9 | 国产在线精品亚洲第一网站| 他把我摸到了高潮在线观看| 欧美中文综合在线视频| 久久人人精品亚洲av| 久久午夜亚洲精品久久| 网址你懂的国产日韩在线| 久久久精品欧美日韩精品| 亚洲在线观看片| 一区福利在线观看| 91麻豆av在线| 天天躁狠狠躁夜夜躁狠狠躁| x7x7x7水蜜桃| 嫩草影视91久久| 欧美乱妇无乱码| 国产精品一区二区精品视频观看| 岛国在线免费视频观看| 欧美绝顶高潮抽搐喷水| 久久久精品欧美日韩精品| 精品国产乱子伦一区二区三区| 久久这里只有精品中国| 一卡2卡三卡四卡精品乱码亚洲| 欧美+亚洲+日韩+国产| 毛片女人毛片| 亚洲 欧美 日韩 在线 免费| 18禁裸乳无遮挡免费网站照片| 不卡av一区二区三区| 淫秽高清视频在线观看| 真人做人爱边吃奶动态| 久久久久久国产a免费观看| 亚洲天堂国产精品一区在线| 国产蜜桃级精品一区二区三区| 国产单亲对白刺激| 日韩精品青青久久久久久| 久久性视频一级片| 日本黄色视频三级网站网址| 丝袜人妻中文字幕| 黑人巨大精品欧美一区二区mp4| 欧美成人性av电影在线观看| 一个人看视频在线观看www免费 | 午夜福利成人在线免费观看| 一级a爱片免费观看的视频| 免费在线观看亚洲国产| 久久久久久人人人人人| 久久天躁狠狠躁夜夜2o2o| 亚洲一区二区三区不卡视频| 九九热线精品视视频播放| 一级毛片女人18水好多| 老汉色av国产亚洲站长工具| 最新在线观看一区二区三区| 国产精品一区二区精品视频观看| 精品不卡国产一区二区三区| 欧美不卡视频在线免费观看| 丁香欧美五月| 在线观看午夜福利视频| 亚洲av成人精品一区久久| 成人国产一区最新在线观看| 搡老妇女老女人老熟妇| 成人亚洲精品av一区二区| 夜夜看夜夜爽夜夜摸| 日韩免费av在线播放| 淫秽高清视频在线观看| 亚洲国产精品久久男人天堂| 国产高潮美女av| 制服丝袜大香蕉在线| 亚洲天堂国产精品一区在线| 欧美一区二区精品小视频在线| 免费大片18禁| 中文字幕最新亚洲高清| 午夜福利高清视频| 91在线精品国自产拍蜜月 | 一本精品99久久精品77| 国产精品免费一区二区三区在线| 国产 一区 欧美 日韩| 日韩欧美一区二区三区在线观看| 日韩欧美国产在线观看| 精品乱码久久久久久99久播| 日本一本二区三区精品| 国产欧美日韩精品亚洲av| 一本精品99久久精品77| 美女高潮喷水抽搐中文字幕| 天堂网av新在线| 丰满人妻一区二区三区视频av | 亚洲午夜理论影院| 国产精品自产拍在线观看55亚洲| 亚洲成av人片在线播放无| a级毛片a级免费在线| 天堂av国产一区二区熟女人妻| 亚洲国产欧洲综合997久久,| 99精品在免费线老司机午夜| 久久久久久国产a免费观看| 成人欧美大片| 久久久久久大精品| 欧美日本视频| 一夜夜www| 成人永久免费在线观看视频| 日日干狠狠操夜夜爽| 亚洲欧美日韩东京热| 日韩欧美免费精品| 成人高潮视频无遮挡免费网站| 国内毛片毛片毛片毛片毛片| 国产精品亚洲美女久久久| 国产欧美日韩精品亚洲av| 天堂影院成人在线观看| 香蕉av资源在线| 欧美另类亚洲清纯唯美| 亚洲美女视频黄频| 色尼玛亚洲综合影院| 久久久成人免费电影| www.熟女人妻精品国产| 在线免费观看的www视频| 最近最新中文字幕大全电影3| 在线永久观看黄色视频| 中文字幕最新亚洲高清| 一二三四社区在线视频社区8| 精品久久久久久久久久免费视频| 哪里可以看免费的av片| 人人妻人人看人人澡| 淫秽高清视频在线观看| 特级一级黄色大片| 99久久无色码亚洲精品果冻| 九九在线视频观看精品| 久9热在线精品视频| 99久久久亚洲精品蜜臀av| 最近在线观看免费完整版| 一区二区三区高清视频在线| 麻豆国产av国片精品| 亚洲成人久久性| 在线观看日韩欧美| 日韩欧美 国产精品| 国产精品美女特级片免费视频播放器 | 久久国产乱子伦精品免费另类| 亚洲一区高清亚洲精品| 国产精品香港三级国产av潘金莲| 精品久久久久久久久久久久久| 宅男免费午夜| 日韩大尺度精品在线看网址| 视频区欧美日本亚洲| 韩国av一区二区三区四区| 叶爱在线成人免费视频播放| 欧美激情久久久久久爽电影| 国模一区二区三区四区视频 | 亚洲成a人片在线一区二区| 久久人人精品亚洲av| 99久久综合精品五月天人人| 日韩欧美一区二区三区在线观看| 欧美一级a爱片免费观看看| 日韩三级视频一区二区三区| 亚洲午夜理论影院| 亚洲七黄色美女视频| 手机成人av网站| 亚洲精品久久国产高清桃花| 亚洲成人久久性| 午夜激情福利司机影院| 亚洲成人中文字幕在线播放| 伦理电影免费视频| 免费高清视频大片| 在线国产一区二区在线| а√天堂www在线а√下载| 欧美不卡视频在线免费观看| 美女cb高潮喷水在线观看 | 亚洲黑人精品在线| 夜夜看夜夜爽夜夜摸| 麻豆成人午夜福利视频| 午夜影院日韩av| 午夜福利成人在线免费观看| 精品乱码久久久久久99久播| 亚洲av中文字字幕乱码综合| 亚洲欧美日韩高清专用| 男人舔女人的私密视频| 中出人妻视频一区二区| 他把我摸到了高潮在线观看| 窝窝影院91人妻| 精品久久久久久久毛片微露脸| 欧美乱色亚洲激情| 亚洲精华国产精华精| 国产午夜福利久久久久久| 亚洲成人久久爱视频| 国产三级在线视频| 国产精品 欧美亚洲| 99精品欧美一区二区三区四区| 可以在线观看毛片的网站| 嫩草影院精品99| 又黄又粗又硬又大视频| 欧美成人一区二区免费高清观看 | 欧美色欧美亚洲另类二区| 18禁黄网站禁片免费观看直播| 亚洲精品乱码久久久v下载方式 | 国产欧美日韩一区二区精品| 人人妻,人人澡人人爽秒播| 国内精品久久久久久久电影| 国产真人三级小视频在线观看| 国产激情久久老熟女| 99热只有精品国产| 麻豆一二三区av精品| 我要搜黄色片| 国产亚洲av高清不卡| 精品熟女少妇八av免费久了| 日韩成人在线观看一区二区三区| 国产av一区在线观看免费| 长腿黑丝高跟| 国产伦一二天堂av在线观看| 色精品久久人妻99蜜桃| 国内少妇人妻偷人精品xxx网站 | 在线永久观看黄色视频| 99久久精品一区二区三区| 国内毛片毛片毛片毛片毛片| 免费av不卡在线播放| 好男人在线观看高清免费视频| 日韩精品青青久久久久久| 人妻久久中文字幕网| 国产精品免费一区二区三区在线| 免费一级毛片在线播放高清视频| 日日干狠狠操夜夜爽| 亚洲国产高清在线一区二区三| 亚洲国产色片| av国产免费在线观看| 最近最新中文字幕大全电影3| 久久久久久国产a免费观看| 一个人看视频在线观看www免费 | 99热精品在线国产| 搡老妇女老女人老熟妇| 久久精品91蜜桃| aaaaa片日本免费| 热99在线观看视频| 国产av麻豆久久久久久久| 男女之事视频高清在线观看| 久久精品91蜜桃| 久久久久性生活片| 热99在线观看视频| 99久久精品一区二区三区| 91在线精品国自产拍蜜月 | 国产欧美日韩精品亚洲av| 国产亚洲精品一区二区www| 嫩草影院入口| 91字幕亚洲| 99热这里只有精品一区 | 午夜久久久久精精品| 成人特级av手机在线观看| 久久久久国产精品人妻aⅴ院| 禁无遮挡网站| 色在线成人网| 国产在线精品亚洲第一网站| 制服丝袜大香蕉在线| 全区人妻精品视频| 免费在线观看成人毛片| 一进一出好大好爽视频| netflix在线观看网站| 色精品久久人妻99蜜桃| 日本五十路高清| 精品久久久久久成人av| 99在线人妻在线中文字幕| 欧美乱色亚洲激情| 亚洲成av人片免费观看| 少妇人妻一区二区三区视频| 91老司机精品| 亚洲欧美一区二区三区黑人| 日本黄大片高清| 狂野欧美激情性xxxx| 亚洲av免费在线观看| 香蕉久久夜色| 美女cb高潮喷水在线观看 | 制服人妻中文乱码| 国产精品av久久久久免费| 在线a可以看的网站| 美女 人体艺术 gogo| 黄色女人牲交| 91在线观看av| 男人的好看免费观看在线视频| av中文乱码字幕在线| 午夜久久久久精精品| 亚洲性夜色夜夜综合| 久久香蕉精品热| 两人在一起打扑克的视频| 久久亚洲精品不卡| 国产成人精品久久二区二区免费| 欧美xxxx黑人xx丫x性爽| 国产精品久久久久久亚洲av鲁大| av黄色大香蕉| 俄罗斯特黄特色一大片| 成年女人看的毛片在线观看| 亚洲第一欧美日韩一区二区三区| www.999成人在线观看| 757午夜福利合集在线观看| 午夜精品久久久久久毛片777| 美女免费视频网站| 脱女人内裤的视频| 亚洲黑人精品在线| 日韩精品青青久久久久久| av黄色大香蕉| 免费观看人在逋| 色哟哟哟哟哟哟| 午夜福利成人在线免费观看| 女生性感内裤真人,穿戴方法视频| 欧美日韩精品网址| 午夜激情福利司机影院| 免费电影在线观看免费观看| 搞女人的毛片| 成人av在线播放网站| 久久这里只有精品中国| netflix在线观看网站| 亚洲五月婷婷丁香| av国产免费在线观看| 国产av麻豆久久久久久久| 中亚洲国语对白在线视频| 神马国产精品三级电影在线观看| 国产 一区 欧美 日韩| 一夜夜www| 国内少妇人妻偷人精品xxx网站 | 淫秽高清视频在线观看| 亚洲人成网站在线播放欧美日韩| 桃色一区二区三区在线观看| 亚洲国产欧洲综合997久久,| 亚洲av五月六月丁香网| 很黄的视频免费| 美女高潮喷水抽搐中文字幕| 久久久久国产精品人妻aⅴ院| 黄色片一级片一级黄色片| 一进一出好大好爽视频| 一个人看视频在线观看www免费 | 91在线观看av| 午夜精品在线福利| 国产又色又爽无遮挡免费看| 成人精品一区二区免费| 十八禁人妻一区二区| 美女大奶头视频| 国产精品电影一区二区三区| 中国美女看黄片| 国产三级在线视频| 国产探花在线观看一区二区| a级毛片在线看网站| 亚洲精品一区av在线观看| 午夜精品一区二区三区免费看| 国产精品久久久久久人妻精品电影| 久久欧美精品欧美久久欧美| 91老司机精品| 亚洲国产欧美一区二区综合| 村上凉子中文字幕在线| 国产激情欧美一区二区| 成人无遮挡网站| 一级a爱片免费观看的视频| 真人做人爱边吃奶动态| 国产精华一区二区三区| 男女下面进入的视频免费午夜| 欧美日本视频| 国产淫片久久久久久久久 | 国产午夜福利久久久久久| 亚洲avbb在线观看| 国产欧美日韩精品亚洲av| 老司机在亚洲福利影院| 美女高潮的动态| 亚洲精品粉嫩美女一区|